Key Data For Amgen Medicines In Relapsed Multiple Myeloma And Acute Lymphoblastic Leukemia To Be Presented At ASH 2015 Data Underscore Company's Commitment to Difficult-to-Treat Blood CancersNew Insights Further Strengthen Evidence of the Role of Kyprolis® (Carfilzomib) in Relapsed Multiple MyelomaGrowing Body of Clinical Evidence Validates Immunotherapy BLINCYTO® (Blinatumomab) for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia